Next generation medical diagnostics enabling lab quality results, in minutes for homes and clinics

GRIP's next generation medical diagnostics

GRIP has developed a novel nucleic acid amplification process that significantly increases the diagnostic accuracy of existing, low-cost, rapid diagnostic tests.

Increases test sensitivity, a critical limitation of today’s rapid, low-cost diagnostic tests
Enables lab-quality results (both sensitivity and specificity), in minutes
Easy to use format
Sample agnostic – urine, nasal secretions, blood saliva, etc.
Adaptable to detect a wide array of pathogens
Low-cost, leverages existing production infrastructure
Increases patient satisfaction, streamlines clinical workflows, and reduces operational costs
Patent pending

GRIP’s amplification process

Simpler, easier to use and lower cost than alternatives

Fast, non-thermal nucleic acid amplification (NTA) is the solution

GRIP’s breakthrough non-thermal nucleic acid amplification process transforms existing lateral flow assays (LFA’s) into lab-quality, cost-effective diagnostic tools for clinics and homes, worldwide.

Looking Ahead

Lab grade results when and where it's needed

Next Generation Diagnostics

Breakthrough Technology

GRIP takes a novel approach to pathogen detection using methods that improve sensitivity yielding more accurate diagnostic results. Our amplification process can be applied to current diagnostic technologies to overcome their inherent shortcomings to deliver actionable medical diagnostic information when and where it matters most – at the point-of-need (clinic, home, eldercare facility, retail pharmacy, etc.)

Clinical value

GRIP’s technology provides actionable medical diagnostic information for multiple diseases in minutes with a single test. This will provide both patients and their physicians access to the information they need to make rapid and fact-based therapy decisions, often without the need for a trip to the clinic.

Easy to use

GRIP’s NTA offers a seamless user experience with no changes to the simple steps you’re already familiar with in today’s in-home diagnostic tests, yet it delivers significantly more insightful results. Designed for use in clinics, homes, eldercare facilities, and pharmacies, it enables the detection of multiple diseases from a single sample.

Cost Effective

The GRIP process is low cost and can be applied to enhance current diagnostic technologies. This reduces development time and expense and enables use of existing manufacturing infrastructure to efficiently and rapidly scale production to meet demand.

Michael Osterholm PhD, MHP University of Minnesota Regents Professor, McKnight Presidential Endowed Chair in Public Health; Author; Clinical Advisor, GRIP Molecular

“There is a need for next-generation medical diagnostics that can be performed by anyone, anywhere, at any time, that provide results of a quality only available today via time and resource consuming test methods and equipment. This would position the healthcare system to respond differently to a future pandemic situation. The GRIP team and their collaborators are working to develop this type of innovative diagnostic technology.”

-Michael Osterholm

GRIP Partners

At home diagnostics

GRIP Story

GRIP is a Minnesota-based molecular diagnostics company founded with the mission of providing lab grade diagnostic results at the time and location of need; the “point-of-need” (e.g. clinic, home, eldercare facility, pharmacy, etc.). Based on years of research in the field, the founder, Bruce Batten, PhD, realized that diagnostic technologies were not ideal for point-of-need diagnostic purposes due to inherent technology constraints that led to tradeoffs of test time, performance and cost. When potential solutions to these challenges were identified, GRIP Molecular was founded in late 2019.
Since then, a highly experienced management and technical team has been assembled, and significant progress has been made to progress these innovative technologies forward to successful commercialization.

"Improving health through better diagnostics"

Core Values

Accountability

We plan and implement with energy and steadfast resolve. We recognize, reward, and hold ourselves, our colleagues, and our partners accountable for the intent and impact of our and their communications and actions.

Leadership

We endeavor to lead in delivering innovative diagnostic solutions in a manner that yields significant societal benefit, employee satisfaction and investor returns in an environmentally responsible manner.

Integrity

We strive to be worthy of trust by always doing what’s right, in the right way, right away.

Respect

We treat all others respectfully, fairly, and empathetically. We value teamwork and diversity and the variety of perspectives it brings.

Balance

We seek a balanced, considered, and well-reasoned approach to business matters and relationships.

"Our actions will speak louder than our words."

Company Status

The Company has successfully raised funds to complete proof-of-concept experiments and retain an experienced management team. It is currently raising funds via a Convertible Note to further these activities. Discussions are underway with various venture capital groups to enter into Series A financing to complete product development and prepare regulatory submissions – 510(k) in the US.

Please call us at 201-783-9355 or send us an email to learn more.